These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31842775)

  • 21. Sero-diagnosis of Mycobacterium avium complex lung disease using serum immunoglobulin A antibody against glycopeptidolipid antigen in Taiwan.
    Shu CC; Ato M; Wang JT; Jou R; Wang JY; Kobayashi K; Lai HC; Yu CJ; Lee LN; Luh KT
    PLoS One; 2013; 8(11):e80473. PubMed ID: 24260398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of patients with bronchoscopy-diagnosed pulmonary Mycobacterium avium complex infection.
    Urabe N; Sakamoto S; Sano G; Ito A; Homma S
    J Infect Chemother; 2018 Oct; 24(10):822-827. PubMed ID: 30054229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical findings in relation to mortality in non-tuberculous mycobacterial infections: patients with Mycobacterium avium complex have better survival than patients with other mycobacteria.
    Kotilainen H; Valtonen V; Tukiainen P; Poussa T; Eskola J; Järvinen A
    Eur J Clin Microbiol Infect Dis; 2015 Sep; 34(9):1909-18. PubMed ID: 26155783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-tuberculous mycobacteriosis. What has been coming out].
    Kajiki A
    Kekkaku; 2011 Feb; 86(2):113-25. PubMed ID: 21404655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between Mycobacterium avium complex lung disease and serum vitamin D status, antimicrobial peptide levels, and bone mineral density.
    Fujita K; Ito Y; Oguma T; Mio T; Niimi A; Hirai T
    Medicine (Baltimore); 2018 Sep; 97(38):e12463. PubMed ID: 30235737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mono- and poly-functional T cells in nontuberculous mycobacteria lung disease patients: Implications in analyzing risk of disease progression.
    Shu CC; Wu LS; Wu MF; Lai HC; Wang PH; Cheng SL; Wang JY; Yu CJ
    Cytokine; 2019 Aug; 120():176-185. PubMed ID: 31085455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of intermittent maintenance therapy after successful treatment of Mycobacterium avium complex lung disease.
    Asakura T; Nakagawa T; Suzuki S; Namkoong H; Morimoto K; Ishii M; Kurashima A; Betsuyaku T; Ogawa K; Hasegawa N;
    J Infect Chemother; 2019 Mar; 25(3):218-221. PubMed ID: 30172726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease: A cross-sectional study.
    Suzuki S; Asakura T; Namkoong H; Okamori S; Yagi K; Kamata H; Uwamino Y; Funatsu Y; Nakano Y; Nishimura T; Ishii M; Ebihara T; Betsuyaku T; Hasegawa N
    Respir Med; 2018 May; 138():1-6. PubMed ID: 29724379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of the radiological severity score in
    Furuuchi K; Ito A; Hashimoto T; Kumagai S; Ishida T
    Int J Tuberc Lung Dis; 2017 Apr; 21(4):452-457. PubMed ID: 28150579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Posttreatment Lymphopenia Is Associated With an Increased Risk of Redeveloping Nontuberculous Lung Disease in Patients With Mycobacterium avium Complex Lung Disease.
    Furuuchi K; Fujiwara K; Uesgi F; Shimoda M; Seto S; Tanaka Y; Yoshiyama T; Yoshimori K; Kurashima A; Ohta K; Morimoto K
    Clin Infect Dis; 2021 Jul; 73(1):e152-e157. PubMed ID: 32507892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical course and risk factors of mortality in Mycobacterium avium complex lung disease without initial treatment.
    Wang PH; Pan SW; Shu CC; Chen CY; Wei YF; Cheng SL; Wang HC; Yu CJ
    Respir Med; 2020 Sep; 171():106070. PubMed ID: 32658834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin 23/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease.
    Shu CC; Wang JY; Wu MF; Lai HC; Chiang BL; Yu CJ
    Tuberculosis (Edinb); 2018 May; 110():7-14. PubMed ID: 29779777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoporosis in nontuberculous mycobacterial pulmonary disease: a cross-sectional study.
    Tanaka H; Asakura T; Suzuki S; Okamori S; Kusumoto T; Ogawa T; Uno S; Morita A; Lee H; Namkoong H; Kamata H; Sato Y; Uwamino Y; Nishimura T; Ishii M; Fukunaga K; Hasegawa N
    BMC Pulm Med; 2022 May; 22(1):202. PubMed ID: 35596169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
    Kadota T; Matsui H; Hirose T; Suzuki J; Saito M; Akaba T; Kobayashi K; Akashi S; Kawashima M; Tamura A; Nagai H; Akagawa S; Kobayashi N; Ohta K
    BMC Infect Dis; 2016 Jan; 16():31. PubMed ID: 26818764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics of pulmonary Mycobacterium avium complex disease diagnosed later in follow-up after negative mycobacterial study including bronchoscopy.
    Koyama K; Ohshima N; Kawashima M; Okuda K; Sato R; Nagai H; Matsui H; Ohta K
    Respir Med; 2015 Oct; 109(10):1347-53. PubMed ID: 26365483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Screening System of Virulent Strains for the Establishment of a
    Furuuchi K; Seto S; Nakamura H; Hikichi H; Miyabayashi A; Wakabayashi K; Mizuno K; Oka T; Morimoto K; Hijikata M; Keicho N
    Microbiol Spectr; 2022 Jun; 10(3):e0045122. PubMed ID: 35579455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of chronic Pseudomonas aeruginosa infection on health-related quality of life in Mycobacterium avium complex lung disease.
    Kamata H; Asakura T; Suzuki S; Namkoong H; Yagi K; Funatsu Y; Okamori S; Uno S; Uwamino Y; Fujiwara H; Nishimura T; Ishii M; Betsuyaku T; Hasegawa N
    BMC Pulm Med; 2017 Dec; 17(1):198. PubMed ID: 29237500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Prognosis and Antimycobacterial Glycolipid Antibody as Biomarker in Mycobacterium avium-intracellulare Complex Pulmonary Disease.
    Maekura R; Miki K; Tateishi Y; Matsumoto S; Kitada S; Miki M; Kida H
    Microbiol Spectr; 2022 Jun; 10(3):e0053022. PubMed ID: 35467367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease.
    Kim OH; Kwon BS; Han M; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW
    Clin Infect Dis; 2019 May; 68(11):1870-1876. PubMed ID: 30239615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease.
    Ye JJ; Wu TS; Chiang PC; Lee MH
    J Microbiol Immunol Infect; 2007 Aug; 40(4):342-8. PubMed ID: 17712469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.